Urine Tests May Be Better Than Serum for Multiple Myeloma Screening, Study Suggests
Urine tests may be better than serum tests to diagnose multiple myeloma or its precursor conditions, because they can spot cases that…
Ana Pena, PhD, — 
Articles by Ana Pena
Twice‐weekly Ninlaro Combo Improves Outcomes in Newly Diagnosed Myeloma Patients, Trial Shows
Twice‐weekly Ninlaro (ixazomib) plus Revlimid (lenalidomide) and dexamethasone can improve long-term outcomes in patients with newly diagnosed multiple…
Pomalyst Triple Combo Delays Disease Progression in Relapsed or Refractory Myeloma Patients, Phase 3 Data Show
Adding Pomalyst (pomalidomide) to a combination of Velcade (bortezomib) and dexamethasone significantly extended…
Recruitment Open for Phase 2 Trial Aimed at Complete Eradication of Myeloma Cells
The University of Alabama at Birmingham (UAB) is recruiting patients with newly diagnosed multiple myeloma for a Phase 2 trial evaluating an…
Selinexor Gains FDA Fast Track Designation for Refractory Multiple Myeloma Patients
Selinexor, the lead oral therapy developed by Karyopharm Therapeutics, received …
SELLAS Vaccine More Than Doubles Time to Myeloma Progression, Phase 2 Trial Shows
SELLAS Life Sciences’ Galinpepimut-S vaccine more than doubles the time it takes for high-risk multiple myeloma patients’ cancer to worsen, a Phase 2 clinical trial shows.
Mouse Study Finds Potential Targets to Minimize Risks of Stem Cell Transplants
Immune factors that drive donor T-cells to cause graft-versus-host disease (GVHD) have been found by researchers whose discovery may offer new opportunities for therapeutic…